Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07, Zacks reports.
Dogwood Therapeutics Stock Down 7.6%
NASDAQ:DWTX opened at $1.83 on Friday. The company has a market cap of $61.12 million, a P/E ratio of -0.17 and a beta of 1.68. Dogwood Therapeutics has a twelve month low of $1.28 and a twelve month high of $9.50. The business has a 50 day moving average price of $2.09 and a two-hundred day moving average price of $3.64.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on DWTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Dogwood Therapeutics in a research note on Monday, April 27th. Weiss Ratings cut Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Dogwood Therapeutics currently has an average rating of “Hold” and an average price target of $12.00.
Institutional Investors Weigh In On Dogwood Therapeutics
An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 9.05% of the company’s stock.
Dogwood Therapeutics Company Profile
Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.
Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.
Featured Stories
- Five stocks we like better than Dogwood Therapeutics
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
